Safety and immunogenicity of the yellow fever vaccine for patients with end-stage renal disease
The outcomes of our study suggest that the yellow YF vaccine is well-tolerated in CKD patients undergoing dialysis, but it does not induce adequate immune response. Future research should focus on evaluating both cellular and humoral immune responses following administration of various doses of the YF vaccine.
Authors
- A. Falqueto (ORCID: https://orcid.org/0009-0009-8044-5504)
- Jesiree Iglésias Quadros Distenhreft (ORCID: https://orcid.org/0000-0002-9313-1899)
- Weverton Machado Luchi (ORCID: https://orcid.org/0000-0001-5762-8921)
- Lauro Monteiro Vasconcellos Filho (ORCID: https://orcid.org/0000-0002-7437-4748)
- Dinair Couto‐Lima (ORCID: https://orcid.org/0000-0003-2043-6306)
- Cecilia S. Andreazzi (ORCID: https://orcid.org/0000-0002-9817-0635)
- Juliana Feu Rosa Carrera Thomazini (ORCID: https://orcid.org/0009-0001-3976-4425)
Institutions
- Universidad Complutense de Madrid (ES)
- Universidade Federal do Espírito Santo (BR)
Publication Details
- Journal
- Brazilian Journal of Nephrology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1590/2175-8239-jbn-2023-0202en
- Citations
- 1
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 0.54